logo
What are the best and worst ice cream bars for your health? Ranking frozen treats — from Drumsticks to frozen yogurt bars

What are the best and worst ice cream bars for your health? Ranking frozen treats — from Drumsticks to frozen yogurt bars

Yahoo4 days ago
They're all tasty. But are any actually good for you?
Whether they're eaten on a long weekend family roadtrip or enjoyed in the backyard after a tasty BBQ, ice cream bars are one of summer's most-loved treats. Given the portability and nostalgia, it's not surprising Canadians are obsessed with these yummy indulgences.
But how do these frozen delights stack up nutritionally — especially if you're trying to watch your sugar and fat intake? Below, we run down how some of the country's most popular frozen treats — including ice cream bars, frozen yogurt and sorbet bars — stack up.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle.
Frozen yogurt bars
Frozen yogurt bars have gotten a major glow-up over the past decade. These days, grocery store shelves sport frozen yogurt treats enrobed in chocolate and featuring jammy fruit swirls. Brands like IOGO offer a little something for your sweet tooth in both dipped and non-dipped varieties. They'll set you back around 100 calories and about 14 per cent of your daily recommended sugar intake.
It's worth noting that unlike un-frozen yogurt, most of these treats don't add much nutritionally to your diet. For example, other than being scant on sugar and fat, the nutritional breakdown of Chapman's frozen yogurt bars clocks only 2 per cent of your daily recommended calcium intake.
If only the real deal will do? For roughly the same amount of fat and calories, you could chow down on a mini-sized ice cream bar.
The takeaway: Frozen yogurt bars are great to scratch the ice cream itch without costing you too much of your daily caloric intake. But they don't have much of an edge in terms of added nutrition.
Frozen fruit and ice bars
Chapman's also sells a frozen sorbet stick dipped in chocolate that looks luscious and stacks up similarly to yogurt bars nutritionally.
Del Monte, meanwhile, makes bars that are mainly frozen fruit puree bars (with a few additives, of course). Each of these bars — which are smaller in size than other brands — are 50 calories a piece, making them a lower (if not the lowest) calorie treat. They're fat-free and even provide a small amount of vitamin — around 5 per cent of your recommended daily value of vitamin C, for example.
You might also be surprised to find out one bar has only 10 grams of sugar. Compliments brand also offers fruit puree bars that are similar nutrition-wise: 80 calories and sugar ranges in the teens — but almost double the size of their Del Monte competitors.
Chapman's Lil Lolly bars are possibly the best-scoring treat: For a mere 40 calories and no fat, you can go for a Popsicle vibe that only has 8 grams of sugar. Considering these bars are essentially frozen flavoured water, this nutritional profile makes sense.
It's up to you if the icier texture of this genre of treat outweighs the numbers: Sometimes that texture is more refreshing, but sometimes you might prefer something richer.
The takeaway: Frozen fruit bars are often the healthiest option you'll find at the grocery store — Del Monte's frozen fruit puree bars are only 50 calories and even have a small amount of vitamin C.
Dipped ice cream bars
Haagen-Daaz. Magnum. Chapman's. This category belongs to the heavy-hitters: Decadent ice cream covered in chocolate, nuts or candy. Naturally, no diet frontrunners are here, but that doesn't mean you need to swear off your favourites.
Haagen-Daaz, the epitome of grocery chain luxury, offers its classic takes — like vanilla in a chocolate-almond coating or vanilla in dark chocolate — in mini form, which carry an almost-identical nutritional breakdown to the average fro-yo bar. Full-size bars — which are 88ml instead of a mini's 55ml — are a different story. They can be around 300 calories and a quarter of your daily recommended sugar intake.
Then there's the maximalist Haagen-Daz EXTRAAS bars: Flavours like key lime pie and salted caramel crunch are slightly smaller than the brand's original line, but carry similar nutritional info, with enough carbs and sugar content to make those calorie-conscious people take note.
Magnum, another high-end treat, carries about half your daily allotment of saturated fat per bar, as well as nearly 20 grams of sugar. The brand's mini bars also have more calories and fat than other bite-sized bars from most competing brands.
Chapman's ice cream bars fare surprisingly similar to their frozen yogurt counterparts; one bar has around 150 calories and 10 grams of sugar. They fall closely in line with Nestle's Parlour dipped bars, which have a mere seven grams of fat, giving more of a middle-road indulgence.
The takeaway: Much akin to the above fro-yo bars, dipped ice cream bars don't offer a ton in terms of adding nutrients to your diet, but unlike those dieter's dreams, these treats generally are more of a spend in terms of calories, fat and sugar.
Frozen ice cream cones
Nestle's Drumsticks — possibly the most iconic in the frozen cone genre — feature more than 15 grams of fat and 20 per cent of your daily sugar allotment. Chapman's Super Cones fair marginally better, but if you're looking for a waffle cone with something to sink your teeth into on top, you'll be looking at a fat content in the teens and sugar in the low 20s.
The takeaway: The fat, sugar and calorie content of these tasty treats makes them a great occasional indulgence. Like their dipped ice cream counterparts, these treats offer little-to-nothing in terms of added nutrients.
The bottom line
So, what to do when your sweet tooth conspires with sultry summer heat to make reaching for ice cream the only option? If you're looking to watch your sugar and fat intake, we suggest going with a frozen yogurt bar or frozen fruit stick — or sticking with a mini size of your favourite ice cream bar.
That said, there's no harm in enjoying the occasional full-sized ice cream bar or Drumstick if you indulge in them as part of a balanced diet.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TikTok trend linked to spike in teen deaths from nitrous oxide misuse, Maryland pharmacist says
TikTok trend linked to spike in teen deaths from nitrous oxide misuse, Maryland pharmacist says

CBS News

time31 minutes ago

  • CBS News

TikTok trend linked to spike in teen deaths from nitrous oxide misuse, Maryland pharmacist says

A growing number of young people are misusing nitrous oxide, also known as laughing gas or whippets, to get high, and a Maryland health expert warns that the consequences can be deadly. A study published July 30 in JAMA Network Open found that U.S. deaths from nitrous oxide jumped by 578% between 2010 and 2023. Last year alone, 156 minors died after inhaling the gas, often from small, presurized canisters sold as whipped cream chargers. Known by brand names like Galaxy Gas, the nitrous oxide canisters are sold online and at gas stations in flavored packaging. On TikTok and other social media platforms, videos of young people inhaling from the canisters have gone viral, drawing concerns from health professionals. "It might seem harmless at first, but it could just take one sitting," said David Berg-Lewis, an emergency medicine clinical pharmacist with LifeBridge Health in Maryland. "You start with a headache or dizziness, but that can quickly lead to seizures, loss of consciousness or even death." Berg-Lewis explained that nitrous oxide cuts off oxygen to the brain, effectively sedating a person's central nervous system. "It deprives people of oxygen," he said. "That's what leads to unconsciousness, suffocation and unfortunately, it can be fatal." The study, conducted by researchers at the University of Mississippi and the University of Illinois Urbana-Champaign, analyzed 14 years of data on nitrous oxide-related deaths from the Centers for Disease Control and Prevention (CDC). The authors of the study noted that the accessibility of the gas, the flavoring and its presence on social media have made it more appealing to young people. "The unconsciousness and suffocation can happen quickly," Berg-Lewis said. "But there are long-term risks too. People can develop numbness and tingling in their hands and legs, weakness, even permanent lung damage." According to Berg-Lewis, the effects depend heavily on the concentration of the gas. "Once the percentage of nitrous oxide in the air hits 80%, you're basically cutting off the brain's oxygen supply," he said. "At that point, someone can slip into an unconscious state." While Berg-Lewis hasn't personally treated a nitrous oxide-related case in the emergency department yet, he said some of his colleagues have, and he hopes he doesn't encounter one. "I mean, using it at all is not good," he said. "But the scary thing is how fast it can go from someone just trying it to a life-threatening situation." The U.S. Food and Drug Administration (FDA) issued a warning earlier this year, listing 15 nitrous oxide products, including Galaxy Gas, as potentially dangerous when misused. However, Berg-Lewis said dozens more are likely on the market, and many are not regulated or clearly labeled.

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Yahoo

timean hour ago

  • Yahoo

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Yahoo

timean hour ago

  • Yahoo

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with type 2 diabetes (T2D) not achieving glycemic targets, icovamenib demonstrated durable HbA1c reduction and improved beta-cell function subsequent to the dosing period In a rodent model of T2D, icovamenib in combination with low-dose semaglutide, promoted enhanced glycemic control and weight loss with complete lean mass preservation Icovamenib promoted healthy myotube morphology and reduced drug-induced atrophy in ex-vivo human myotube cultures Next-generation oral GLP-1 receptor agonist (RA) candidate, BMF-650, demonstrated robust, dose-dependent weight loss and appetite suppression in obese non-human primates; planned Investigational New Drug (IND) submission remains on track for the second half of 2025 Raised approximately $42.8 million in gross proceeds through a public offering, extending projected cash runway into the second half of 2026 Reduced the workforce and quarterly expenses to support the advancement of the ongoing core programs SAN CARLOS, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea' or 'Biomea Fusion' or 'the Company') (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the second quarter ended June 30, 2025, and provided a business update. 'In the second quarter, we presented clinical and preclinical results with icovamenib that support its unique role as a novel, potentially first-in-class investigational agent for the treatment of type 2 diabetes as well as in obesity, while further strengthening our BMF-650 program with robust data in non-human primates,' said Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member of Biomea Fusion. 'At ADA 2025, we showed in preclinical models that our menin inhibitor, icovamenib, in combination with low-dose semaglutide not only drove superior glycemic control but also considerably boosted weight reduction, while fully preserving lean mass and outperforming semaglutide alone. Furthermore, icovamenib promoted myotube health and reduced drug-induced atrophy in a human cell model, highlighting its potential to support muscle health. We look forward to engaging with FDA and further evaluating icovamenib in this patient setting. Our next-generation investigational GLP-1 RA, BMF-650, showed encouraging results in a 28-day study in obese cynomolgus monkeys, achieving up to 15% weight reduction and robust dose-dependent appetite suppression. These findings reinforce BMF-650's potential as an oral GLP-1 RA. With these clinical advances and the completion of our $42.8 million equity financing, we now have the necessary resources to advance these high-priority diabetes and obesity programs.' Second Quarter Highlights: Icovamenib (Oral Small Molecule Menin Inhibitor for T2D and Type 1 Diabetes (T1D)) Three presentations at ADA 2025 highlighted the therapeutic potential of icovamenib across multiple aspects of metabolic health: In patients with T2D not achieving glycemic targets, icovamenib demonstrated durable HbA1c reduction and enhanced beta-cell function three months subsequent to the dosing period, particularly in severe insulin deficient patients enrolled in its Phase II trial; icovamenib was well tolerated across the dosing arms. In a Zucker Diabetic Fatty (ZDF) rat model of T2D, treatment of icovamenib in combination with low-dose semaglutide delivered superior metabolic benefits compared to low-dose semaglutide alone: 60% lower fasting blood glucose and 50% lower glucose OGTT AUC Greater HbA1c decline of >1% by Day 28 and >2% by Day 39 Greater improvement in insulin sensitivity with a 75% lower HOMA-IR (marker of insulin resistance) 2-fold increase in C-peptide to glucose ratio indicating enhanced beta cell function Superior appetite suppression with a 10% greater body weight reduction than low-dose semaglutide alone The observed body weight loss was primarily due to fat mass reduction with complete preservation of lean mass Icovamenib also promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo human myotube cultures. BMF-650 (Next-generation Oral Small Molecule GLP-1 RA for Obesity) In a 28-day study in obese cynomolgus monkeys, BMF-650 achieved rapid, dose-dependent reductions in food intake and significant weight loss, with average weight reductions of 15% at the higher dose of 30 mg/kg/day. BMF-650 was generally well tolerated across all dose levels and showed no aminotransferase elevations. These preclinical results compare favorably to published preclinical data from other leading oral GLP-1 RA candidates in development and support BMF-650's potential as a best-in-class oral small-molecule GLP-1 RA. BMF-500 (Oral Small Molecule FLT3 Inhibitor in Acute Myeloid Leukemia (AML)) Presented updated Phase I data at EHA 2025, showing sustained antileukemic responses, deep bone marrow blast reductions, and survival benefit in relapsed/refractory FLT3-mutant AML patients, all of whom had failed FLT3 inhibitor gilteritinib. The Company concluded its oncology efforts and is now exploring strategic partnerships for BMF-500. Financing & Operations In June 2025, Biomea closed its previously announced underwritten public offering and in July 2025 the underwriters partially exercised their over-allotment option to purchase additional shares of common stock. The aggregate gross proceeds from the offering, including the over-allotment option, were approximately $42.8 million, before deducting underwriting discounts and commissions and offering expenses payable by Biomea. During the first half of 2025 Biomea also reduced its workforce and operational expenses and anticipates future quarterly operational expenses to be approximately 40% lower than the most recent quarter, depending on study enrollments and expansion. Key Anticipated 2025 Milestones: Icovamenib (Oral Small Molecule Menin Inhibitor for T2D and T1D) 52-week data from the Phase II COVALENT-111 study in T2D expected in the second half of 2025. Initiation of Phase II study of icovamenib in T2D patients currently uncontrolled on a GLP-1 based therapy in the second half of 2025. Preliminary data from the Phase II COVALENT-112 study in T1D anticipated in the second half of 2025. BMF-650 (Next-generation Oral Small Molecule GLP-1 RA for Obesity) Submission of the IND application for BMF-650 is planned for the second half of 2025. Phase I study initiation in obese, otherwise healthy volunteers anticipated by late 2025, pending regulatory clearance. Second Quarter 2025 Financial Results Cash, Cash Equivalents, and Restricted Cash: As of June 30, 2025, the Company had cash, cash equivalents and restricted cash of $56.6 million. The Company expects its cash, cash equivalents, and restricted cash to be sufficient to fund planned operating activities into the second half of 2026. Net Loss: The Company reported a net loss attributable to common stockholders of $20.7 million for the three months ended June 30, 2025, which included $2.6 million of stock-based compensation, compared to a net loss of $37.3 million for the same period in 2024, which included $4.8 million of stock-based compensation. Net loss attributable to common stockholders was $50.0 million for the six months ended June 30, 2025, which included $5.7 million of stock-based compensation, compared to a net loss of $76.3 million for the same period in 2024, which included $9.9 million of stock-based compensation. Research and Development (R&D) Expenses: R&D expenses were $16.6 million for the three months ended June 30, 2025, compared to $31.8 million for the same period in 2024. The decrease of approximately $15.3 million was primarily driven by a decrease of $9.1 million related to clinical activities, a decrease of $2.0 million related to preclinical and exploratory programs, a decrease of $0.1 million of manufacturing costs and a decrease of $0.2 million in other external costs related to consultants, advisors and other professional services to support our clinical studies. Personnel-related expenses decreased by $3.8 million, including stock-based compensation, due to a decrease in headcount. R&D expenses were $39.5 million for the six months ended June 30, 2025, compared to $65.6 million for the same period in 2024. The decrease of $26.1 million was primarily driven by a decrease of $16.4 million related to clinical activities, a decrease of $3.0 million related to preclinical and exploratory programs and a decrease of $1.9 million of manufacturing costs. This decrease in external costs was partially offset by an increase of $0.7 million in other external costs related to consultants, advisors and other professional services to support our clinical studies. Personnel-related expenses decreased by $5.5 million, including stock-based compensation, due to a decrease in headcount. General and Administrative (G&A) Expenses: G&A expenses were $4.7 million for the three months ended June 30, 2025, compared to $7.1 million for the same period in 2024. The decrease of $2.4 million is primarily driven by a decrease of $1.9 million related to personnel-related expenses, including stock-based compensation, due to a decrease in headcount and a decrease of $0.4 million related to professional and legal services. G&A expenses were $11.5 million for the six months ended June 30, 2025, compared to $14.4 million for the same period in 2024. The decrease of $2.8 million is primarily driven by a decrease of $2.9 million related to personnel-related expenses, including stock-based compensation, due to a decrease in headcount. About Biomea FusionBiomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both being developed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. We aim to cure. Visit us at and follow us on LinkedIn, X and Facebook. Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the expected benefits resulting from the implementation of the cost saving measures and potential ability to fund key value drivers; clinical and therapeutic potential of our product candidates and development programs, including icovamenib, BMF-500, and BMF-650, the potential of icovamenib as a treatment for T1D and T2D, the potential of BMF-650 as a treatment for diabetes and obesity; our research, development and regulatory plans; the mechanism of action of our product candidates and development programs; the progress and initiation of our ongoing and upcoming clinical trials, including our Phase I/II COVALENT-111 study of icovamenib in T2D, our Phase II COVALENT-112 study of icovamenib in T1D, and our planned IND submission for the BMF-650 program; the anticipated availability of data from our clinical trials; our planned interactions with regulators, and the timing of such events; and our expected cash runway may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that preliminary or interim results of preclinical studies or clinical trials may not be predictive of future or final results in connection with future clinical trials and the risk that we may encounter delays in preclinical or clinical development, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea Fusion's business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission ('SEC'), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact: Meichiel Jennifer WeissSr. Director of Investor Relations and Corporate Development mweiss@ BIOMEA FUSION, INC. Condensed Statement of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development (1) $ 16,566 $ 31,825 $ 39,463 $ 65,601 General and administrative (1) 4,710 7,073 11,525 14,356 Total operating expenses 21,276 38,898 50,988 79,957 Loss from operations (21,276 ) (38,898 ) (50,988 ) (79,957 ) Interest and other income, net 536 1,622 986 3,620 Net loss and comprehensive loss $ (20,740 ) $ (37,276 ) $ (50,002 ) $ (76,337 ) Net loss per common share, basic and diluted $ (0.51 ) $ (1.03 ) $ (1.29 ) $ (2.12 ) Weighted-average number of shares used to compute basic and diluted net loss per common share 40,630,403 36,043,561 38,639,834 35,966,965 (1) Includes stock-based compensation as follows (non-cash operating expenses): Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Research and development $ 1,568 $ 2,448 $ 3,488 $ 4,994 General and administrative 1,005 2,392 2,254 4,868 Total stock-based compensation expense $ 2,573 $ 4,840 $ 5,742 $ 9,862 BIOMEA FUSION, INC. Condensed Balance Sheet Data (Unaudited) (in thousands) June 30, December 31, 2025 2024 Cash, cash equivalents, and restricted cash $ 56,593 $ 58,648 Working capital 47,095 46,659 Total assets 73,163 79,938 Stockholders' equity 27,510 51,573

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store